SAN

79.77

+2.37%↑

UCB

254.2

+2.46%↑

SHL.DE

36.79

+0.19%↑

ARGX

599

+2.85%↑

VIE

32.27

+1.8%↑

SAN

79.77

+2.37%↑

UCB

254.2

+2.46%↑

SHL.DE

36.79

+0.19%↑

ARGX

599

+2.85%↑

VIE

32.27

+1.8%↑

SAN

79.77

+2.37%↑

UCB

254.2

+2.46%↑

SHL.DE

36.79

+0.19%↑

ARGX

599

+2.85%↑

VIE

32.27

+1.8%↑

SAN

79.77

+2.37%↑

UCB

254.2

+2.46%↑

SHL.DE

36.79

+0.19%↑

ARGX

599

+2.85%↑

VIE

32.27

+1.8%↑

SAN

79.77

+2.37%↑

UCB

254.2

+2.46%↑

SHL.DE

36.79

+0.19%↑

ARGX

599

+2.85%↑

VIE

32.27

+1.8%↑

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Suletud

26.9 6.96

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

25.1

Max

28.95

Põhinäitajad
By Trading Economics
Sissetulek	-5.4M
Müük	27M
Kasumimarginaal	-20.208
Töötajad	103
EBITDA	1.1M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	-9.45% downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	1. apr 2026

Turustatistika
By TradingEconomics
Turukapital	1.3B
Eelmine avamishind	19.94
Eelmine sulgemishind	26.9

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. märts 2026, 20:20 UTC

Omandamised, ülevõtmised, äriostud

Infosys Agrees to Acquire Stratus

25. märts 2026, 23:58 UTC

Tulu

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

25. märts 2026, 23:58 UTC

Tulu

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

25. märts 2026, 23:57 UTC

Tulu

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

25. märts 2026, 23:57 UTC

Tulu

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

25. märts 2026, 23:56 UTC

Tulu

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

25. märts 2026, 23:56 UTC

Tulu

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

25. märts 2026, 23:41 UTC

Market Talk

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

25. märts 2026, 23:41 UTC

Tulu

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

25. märts 2026, 23:34 UTC

Market Talk

Uudisväärsed sündmused

Gold Declines on Possible Technical Correction -- Market Talk

25. märts 2026, 22:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25. märts 2026, 22:08 UTC

Market Talk

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

25. märts 2026, 21:58 UTC

Market Talk

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

25. märts 2026, 21:37 UTC

Market Talk

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

25. märts 2026, 21:14 UTC

Omandamised, ülevõtmised, äriostud

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

25. märts 2026, 21:13 UTC

Omandamised, ülevõtmised, äriostud

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

25. märts 2026, 21:12 UTC

Omandamised, ülevõtmised, äriostud

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

25. märts 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

25. märts 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

25. märts 2026, 20:33 UTC

Omandamised, ülevõtmised, äriostud

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

25. märts 2026, 20:31 UTC

Tulu

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

25. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

25. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

25. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

25. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

-9.45% langus

12 kuu keskmine prognoos

Keskmine 23 EUR -9.45%

Kõrge 23 EUR

Madal 23 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.